L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases

Neuroscience Letters
Maddalena NapolitanoAlberto Gulino

Abstract

The dopamine (DA) precursor L-DOPA remains the most common treatment for Parkinson's disease (PD). However, long-term treatment with L-DOPA induces dyskinesia and motor disabilities in PD patients, indicating that this pharmacological agent is unable to fully compensate for the effects of DA denervation when used chronically. In this study, we examined the effect 6-hydroxydopamine (6-OHDA)-induced DA denervation of the striatum followed by either acute or chronic treatment with L-DOPA on gene expression of critical regulators of glutamate synaptic transmission. We found that administration of L-DOPA in rats with unilateral DA denervation resulted in a progressive increase of contraversive circling behavior and modulated the expression of Src, Lyn and PKC kinases. In particular, acute (3 days) and chronic (21 days) L-DOPA treatment were differentially able to rescue the effects of DA lesion, since only the acute treatment with L-DOPA corrected the decrease in Src, Lyn and PKC kinase expression induced by 6-OHDA lesion. Also, the reduced phosphorylation level of NR1 receptor subunit induced by 6-OHDA was only partially reversed by chronic L-DOPA treatment.

References

Oct 29, 2000·Trends in Neurosciences·P CalabresiG Bernardi
Apr 1, 2003·Nature Neuroscience·Barbara PicconiPaolo Calabresi
Oct 12, 2004·Neurobiology of Disease·Christine KonradiM Angela Cenci

❮ Previous
Next ❯

Citations

Oct 17, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C Anthony AltarStephen D Ginsberg
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Peter Jenner
Nov 9, 2011·The FEBS Journal·Bradley R GrovemanXianMin Yu
Dec 30, 2014·Fundamental & Clinical Pharmacology·Amit KumarNirmal Singh
May 26, 2017·Expert Opinion on Investigational Drugs·Silvia CerriFabio Blandini
Oct 7, 2018·The Journal of Pharmacology and Experimental Therapeutics·F GardoniC Keywood
Jan 16, 2013·Pharmacological Reviews·Philippe HuotJonathan M Brotchie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.